corporate site
TENACIOUSLY WORKING
TO FIGHT VIRAL THREATS

Press Releases

September 8, 2026
Invivyd to Participate in Upcoming September Investor Conferences
September 3, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
September 1, 2026
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
August 13, 2026
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 4, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
July 6, 2026
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 2, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2026
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
June 9, 2026
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
June 3, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 30
Print
Contact IR
RSS
Email Alerts